We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current TROV market cap is 53.17M. The company's latest EPS is USD -0.9281 and P/E is -1.28.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 141k | 156k | 205k | 163k | 164k |
| Operating Income | -10.63M | -10.33M | -10.93M | -12.55M | -12.6M |
| Net Income | -9.74M | -9.34M | -10.02M | -11.78M | -11.86M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 245k | 366k | 359k | 386k | 488k |
| Operating Income | -16.68M | -19.09M | -28.86M | -39.9M | -45.41M |
| Net Income | -16.71M | -22.6M | -28.32M | -38.73M | -41.47M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 88.45M | 81.64M | 74.04M | 66.05M | 62.9M |
| Total Liabilities | 10.63M | 11.9M | 13.14M | 13.66M | 13.5M |
| Total Equity | 77.83M | 69.74M | 60.89M | 52.39M | 49.39M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 13.09M | 134.73M | 149.54M | 116.19M | 81.64M |
| Total Liabilities | 5.78M | 6.57M | 9.13M | 9.85M | 11.9M |
| Total Equity | 7.31M | 128.16M | 140.42M | 106.34M | 69.74M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -23.75M | -30.89M | -7.74M | -16.97M | -27.43M |
| Investing | 22.63M | 36.2M | 4.64M | 18.65M | 9.22M |
| Financing | N/A | N/A | 107k | 2.17M | 9.59M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -13.27M | -16.32M | -23.04M | -33.82M | -30.89M |
| Investing | -68k | -212k | -131.45M | 38.15M | 36.2M |
| Financing | 12.08M | 137.31M | 35.45M | 75k | N/A |
| Market Cap | 53.17M |
| Price to Earnings Ratio | -1.28 |
| Price to Sales Ratio | 109.17 |
| Price to Cash Ratio | 2.46 |
| Price to Book Ratio | 0.76 |
| Dividend Yield | - |
| Shares Outstanding | 44.68M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.08 (6.4%) |
| Company Name | TrovaGene Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://cardiffoncology.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
